We are currently enrolling for a Phase 2 trial in molluscum contagiosum under NCT03186378.
Verrica is advancing its lead product VP-102, a proprietary topical therapy, in a number of common skin indications including Molluscum contagiousum and Verruca Vulgaris (common warts and plantar warts). Our lead product VP-102 is a topical that is applied directly to the lesions. Verrica is also pursuing additional common dermal indications including Actinic Keratosis and Seborrheic Keratosis. VP-102 is designed to be convenient for both patients and practitioners.